Gilead Sciences Inc at Jefferies London Healthcare Conference Transcript

Nov 15, 2023 / 09:00AM GMT
Michael Jonathan Yee - Jefferies LLC, Research Division - Equity Analyst

Okay. Good morning. Thank you, everyone, for joining us on the morning session here on day 2 of the Jefferies Global London Healthcare Conference. I'm Mike Yee, one of the biotech analysts at Jefferies, and I'm really pleased to have with us up here on the stage, the Chief Financial Officer of Gilead Sciences, Andy Dickinson. Andy, great to have you with us.

Questions and Answers:

Michael Jonathan Yee - Jefferies LLC, Research Division - Equity Analyst

I would love to just maybe take a step back, talk about your outlook on 2024, but really sort of summarizing how Gilead has been positioned in 2023. You just reported earnings a couple of weeks ago. A lot of people are obviously thinking about growth at Gilead, core business, pipeline and how you're positioned for 2024.

So maybe just coming away from third quarter, give us a snapshot about how you're feeling about things. And we'll get in a little more of the details.

Andrew D. Dickinson - Gilead
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot